Under multiple pressures, pharmaceutical companies still have strong demand for medical representatives

The persistently high sales expenses of listed pharmaceutical companies have become a chronic disease in the industry.
In order to solve this problem, anti-corruption of pharmaceuticals has been regarded as the most important work in the industry in recent years, and the intensity is constantly escalating
.
It is understood that since this year, a number of regulations have been promulgated to regulate the practice of medical practitioners in the field of pharmaceutical purchase and sales
.
As some time ago, the National Health Commission and other three departments jointly issued the "Notice on Printing and Distributing the Nine Guidelines for the Clean Practice of Staff in Medical Institutions".
High-quality development of health services
.
On October 20, the Central Commission for Discipline Inspection also issued a document stating that it is deeply concerned about the positive trends in the field of pharmaceutical purchases and sales
.
It mentioned that with the introduction of "heavy punch" policies one after another by the regulatory authorities, the profession of medical representatives has ushered in a special moment of "transformation or disappearance", and the era of "middlemen earning the difference" is coming to an end
.
The analysis believes that, from the perspective of relevant policies and regulations, although the main actions to be cracked down are medical representatives' violations of laws and regulations, they have not denied all the work of medical representatives
.
But as a whole, affected by the escalation of anti-corruption of medicines and the squeeze of centralized procurement, the survival space of 3 million medicines has become smaller and smaller
.
It is understood that in recent years there have been more and more news about the abolition of sales teams by pharmaceutical companies, including some large companies
.
The analysis believes that, as a whole, under the remediation of the industry, the medical environment will become more professional, and the compliance pressure of medical representatives will continue to escalate, and it is urgent to return to the academic standard
.
In this context, 3 million medical representatives may be reduced to around 500,000
.
But generally speaking, this profession will not disappear.
Pharmaceutical companies still need professional medical representatives to process information and promote new drugs
.
In particular, innovative drug companies and leading multinational pharmaceutical companies will need experienced professional medical representatives to carry out the promotion of new drugs
.
In fact, from the recent recruitment announcements of many pharmaceutical companies, it can be seen that the demand for the position of pharmaceutical representatives is still very strong.

.
It is reported that the Cinda Bio&Blood team is currently recruiting medical representatives to be responsible for Dabova (rituximab) and third-generation Tki (oribatinib) to be listed at the end of the year
.
Xi'an Janssen Pharmaceutical Co.
, Ltd.
is also recruiting senior pharmaceutical representatives to be responsible for new urology products with good market prospects
.
In addition, Sino-US East China, CSPC, Enhai Baijin, and Abbott (Shanghai) Trading Co.
, Ltd.
have also released relevant recruitment information
.
The analysis believes that from the current recruitment positions of major pharmaceutical companies, pharmaceutical companies are indeed paying more attention to the delivery of product information and increasing sensitivity to the market
.
Therefore, in order to stabilize revenue, the goal of many pharmaceutical companies in the future will be to accelerate the increase in product sales, or to strengthen the building of marketing teams and conduct professional marketing to continuously increase regional coverage and market share
.
Affected by this, the demand for medical representatives and senior medical talents is expected to grow stronger
.